Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)

Summary

This is a trial of tirzepatide in people with obesity and knee osteoarthritis. The main purpose of this study is to see if tirzepatide can reduce number of these participants who require a knee replacement. Participants will be randomized to take a weekly injection of tirzepatide or a placebo for a total of 72 weeks.

Timeline

Start

2024-11-19

Primary completion

2027-05

Completion

2037-05

Publications

• Ursini F, Ciaffi J, Caporali R. If the evidence is there, why are GLP-1 receptor agonists not on-label for hip and knee osteoarthritis in overweight patients? RMD Open. 2025 Sep 23;11(3):e006025. doi: 10.1136/rmdopen-2025-006025.

Drugs

Indications